These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33404141)

  • 21. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
    Kumari S; Manalai P; Leong S; Wooditch A; Malik M; Lawson WB
    Am J Addict; 2016 Mar; 25(2):110-7. PubMed ID: 26749158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploratory Economic Evaluation of Buprenorphine Treatment in Opioid Use Disorder.
    Elarabi HF; Al Ghaferi H; Hasan N; Lee AJ; Shawky M; Al Kathiri H; Elrasheed A; Al Maamari S; Gawad TA; Radwan D; Adem A; Marsden J
    J Ment Health Policy Econ; 2021 Sep; 24(3):89-95. PubMed ID: 34554106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
    Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
    Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
    ESUB-MG Study Group
    BMC Fam Pract; 2016 Mar; 17():24. PubMed ID: 26931763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
    Iheanacho T; Payne K; Tsai J
    Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.
    Hammond CJ; Park G; Kady A; Rathod K; Rahman N; Vidal C; Wenzel K; Fishman M
    J Subst Abuse Treat; 2022 Feb; 133():108495. PubMed ID: 34218992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.
    Gerra G; Borella F; Zaimovic A; Moi G; Bussandri M; Bubici C; Bertacca S
    Drug Alcohol Depend; 2004 Jul; 75(1):37-45. PubMed ID: 15225887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are patients' goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder.
    Rosic T; Naji L; Panesar B; Chai DB; Sanger N; Dennis BB; Marsh DC; Rieb L; Worster A; Thabane L; Samaan Z
    BMJ Open; 2021 Jan; 11(1):e044017. PubMed ID: 33436476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
    Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
    Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
    Ling W; Nadipelli VR; Aldridge AP; Ronquest NA; Solem CT; Chilcoat H; Albright V; Johnson C; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2020; 14(5):e233-e240. PubMed ID: 32187112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
    Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
    Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
    Chawarski MC; Mazlan M; Schottenfeld RS
    Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.